Search results
Given that neuropsychiatric symptoms in children may be attributed to a wide variety of conditions and possible triggers, it is imperative that knowledge of this common ADR of montelukast be disseminated not only to paediatric respirologists but also to paediatricians and primary care providers.
9 wrz 2024 · Montelukast treatment could have been ineffective for asthma and/or allergic rhinitis, montelukast could have caused other side effects, or patients did not prefer to take montelukast. In conclusion, children and adolescents with allergic rhinitis should be prescribed montelukast with caution considering its clinical benefits.
In this issue of the European Respiratory Journal, BENARD et al. [4] examine the frequency and relative risk of neuropsychiatric adverse events in children prescribed montelukast, as compared to ICS, in the real-world setting of a paediatric asthma clinic.
Montelukast, the only LTRA licensed for use in children aged <12 years appears to be generally well tolerated with side-effects primarily limited to minor gastrointestinal disturbances, respiratory symptoms, skin reactions and headaches ; importantly, the absence of growth and adrenal suppression increases its appeal for children with asthma.
4 cze 2023 · Adverse Effects. Montelukast is relatively well-tolerated and generally safe. The most commonly observed side effects in patients aged 15 years and over were headaches, influenza infection, abdominal pain, cough, and dyspepsia. In children, diarrhea, nausea, laryngitis, pharyngitis, sinusitis, otitis, and viral infection may occur.
20 wrz 2017 · Montelukast, a selective leukotriene receptor antagonist, is recommended in guidelines for the treatment of asthma in both children and adults. However, its effectiveness is debated, and recent studies have reported several adverse events such as neuropsychiatric disorders and allergic granulomatous angiitis.
22 mar 2023 · Indications. Montelukast is an orally dosed drug (available as a film-coated tablet, chewable tablet, or oral granules) that is FDA-approved for treating the following conditions. Asthma: Monteleulast is indicated for asthma prophylaxis and chronic treatment in adults and pediatric patients 12 months of age and older. [1] [2]
